Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma

Autor: Olle Ringdén, Roberto Crocchiolo, Fleischhauer K, Marco Bregni, Omasic B, Silvia Gregori, Benedetta Mazzi, Didier Blaise, Jacopo Peccatori, L Barkholt, J.-O. Bay, Christophe Picard, Fabio Ciceri, Giada Amodio, Trinca S
Přispěvatelé: Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Crocchiolo, R., Ringden, O., Bay, J. -O., Blaise, D., Omasic, B., Mazzi, B., Picard, C., Trinca, S., Barkholt, L., Peccatori, J., Gregori, S., Amodio, G., Fleischhauer, K., Ciceri, F., Bregni, M.
Rok vydání: 2017
Předmět:
Adult
Male
0301 basic medicine
Oncology
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
Medizin
Hematopoietic stem cell transplantation
Human leukocyte antigen
Malignancy
Young Adult
03 medical and health sciences
0302 clinical medicine
Renal cell carcinoma
HLA-G
Internal medicine
medicine
Carcinoma
Humans
Neoplasm Metastasis
Carcinoma
Renal Cell
Survival rate
Aged
HLA-G Antigens
Transplantation
Polymorphism
Genetic
business.industry
Hazard ratio
Hematopoietic Stem Cell Transplantation
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Hematology
Middle Aged
medicine.disease
3. Good health
Survival Rate
Treatment Outcome
030104 developmental biology
Female
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
030215 immunology
Zdroj: Bone Marrow Transplantation
Bone Marrow Transplantation, Nature Publishing Group, 2018, 53 (2), pp.213-218. ⟨10.1038/bmt.2017.243⟩
ISSN: 1476-5365
0268-3369
DOI: 10.1038/bmt.2017.243
Popis: International audience; Renal cell carcinoma (RCC) is particularly sensitive to immune intervention. HLA-G, a non-classical HLA class I molecule with immunomodulatory properties, has been studied with regard to outcome after hematopoietic stem cell transplantation (HSCT), in particular the 14 bp insertion/deletion polymorphism in the 3' untranslated region. Here we analyzed n=56 patients affected by metastatic RCC who received an allogeneic HSCT between 1998 and 2006 in Milano, Marseille, Clermont-Ferrand and Stockholm. The 14 bp polymorphism was analyzed in correlation with overall survival (OS), PFS, acute and chronic GvHD. With a median follow-up of 13 years, a trend towards better outcome was observed when homozygosity for the 14bp-del allele was present: multivariate hazard ratio was 0.50 (95% confidence interval (CI): 0.23-1.13; P=0.10) and 0.57 (95% CI: 0.26-1.26; P=0.17) for OS and PFS, respectively, when 14bp-del/del was compared with 14bp-ins/X. Further exploratory analysis revealed a significant association between T/C at p3003 and improved OS (P=0.05) and PFS (P=0.006) compared with T/T. To our knowledge this is the first study on HLA-G and outcome after HSCT for a solid malignancy. After a coordinated multicenter study, we found that the more tolerogenic polymorphisms (14bp-del/del) is associated with better PFS and OS. The finding on p3003 deserves further investigation.Bone Marrow Transplantation advance online publication, 13 November 2017; doi:10.1038/bmt.2017.243.
Databáze: OpenAIRE
Externí odkaz: